Aiming at the Tangle’s Heart? DIAN-TU Trial to Torpedo Tau’s Core (Links to an external site)
Encouraging findings in Alzheimer’s prevention trial lead to the next phase (Links to an external site)
International Alzheimer’s clinical trial to test tau drugs (Links to an external site)
Bateman, Diamond, Hultgren named to National Academy of Inventors (Links to an external site)
School of Medicine scientists honored for innovation
Dementia First blood test to help diagnose Alzheimer’s goes on sale (Links to an external site)
Barch, Bateman elected to National Academy of Medicine (Links to an external site)
AAIC 2020, dallo studio DIAN-TU la terapia contro l’Alzheimer (Links to an external site)
Elixir Factor Podcast S2 Ep6: Dominantly Inherited Alzheimer’s Disease: A View From Within (Links to an external site)
Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a rare, inherited form of Alzheimer’s disease has demonstrated that one of the drugs had a positive impact on biomarkers of the disease. The study (ClinicalTrials.gov Identifier: NCT01760005) is a phase 2/3 trial led by Washington […]
In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned (Links to an external site)
Confused About the DIAN-TU Trial Data? Experts Discuss Nuances (Links to an external site)
Topline Result for First DIAN-TU Clinical Trial: Negative on Primary (Links to an external site)
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates (Links to an external site)
DIAN-TU Mcdade: “Nel 2020 sapremo se possiamo bloccare l’Alzheimer” (Links to an external site)
Importante estudio en enfermedad de Alzheimer abrirá 5 nuevos sitios latinoamericanos (Links to an external site)
Major Alzheimer’s study to open 5 new Latin American sites (Links to an external site)
Why Didn’t She Get Alzheimer’s? The Answer Could Hold a Key to Fighting the Disease (Links to an external site)
‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab (Links to an external site)
Wash U leading worldwide Alzheimer’s study (Links to an external site)
The importance of prevention trials in Alzheimer’s disease with Randall Bateman (Links to an external site)
Blood test is highly accurate at identifying Alzheimer’s before symptoms arise (Links to an external site)
2019 DIAD Family Conference: Mutation, Participation, Innovation (Links to an external site)
Bateman receives Potamkin Award for Alzheimer’s research (Links to an external site)
The heartbreak and heroism of being the X-Men in Alzheimer’s disease (Links to an external site)
Timeline of the the Dominantly Inherited Alzheimer Network (Links to an external site)
‘Everything is for Alexis’: She is not yet 2. Her father fears she will have Alzheimer’s. (Links to an external site)
Andres Martin, a 31-year-old Marine, is being treated at Walter Reed National Military Medical Center for a rare form of Alzheimer’s disease that impacts people with roots in Jalisco, Mexico. He worries his daughter, Alexis, who is not yet 2, will also have it.
Early Clues (Links to an external site)
Update on the DIAN-TU-001 TRIAL
Update on the DIAN-TU-001 TRIAL: Janssen BACE Inhibitor (JNJ-54861911/atabecestat) DRUG ARM DISCONTINUATION The statement below is an update to the May 25th announcement found on Janssen’s website. Previously, Janssen observed elevations of liver enzymes in some study participants who received atabecestat, including two patients who had high elevations of liver enzymes, placing them at increased […]
DIAN-TU Trial Interim Analysis
Notice to DIAN-TU Investigational Sites and Participants RE: DIAN-TU-001 INTERIM ANALYSIS April 25, 2018 DIAN-TU Site Leaders and Participants, The original goal and intent of the biomarker interim analysis was to determine if the investigational drugs at the dosages used were modifying the amyloid-beta targets. The biomarker Interim Analysis was designed to allow the DIAN-TU […]